Dopamine agonists situation in Parkinson disease;Situación de los agonistas dopaminérgicos en la enfermedad de Parkinson

Revista de Neurologia

Volumn 33, Issue 11, 2001, Pages 1071-1093

  Barbanoj, Manuel ^a   Campos Arillo, Víctor M ^a   Giménez Roldán, Santiago ^a   Linazasoro Cristóbal, Gurutz ^a   Luquin Piudo, Ma Rosario ^a   Vela Desojo, Lydia ^a   Kulisevsky, Jaume ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Dopamine agonists; Dyskinesia; Parkinson disease; Ropinirol

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE;

CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; HUMAN; MONOTHERAPY; MOTOR DYSFUNCTION; PARKINSON DISEASE; REVIEW; TREATMENT OUTCOME;

EID: 0035709908     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3311.2001147     Document Type: Review

References (114)

1. Tratamiento de la enfermedad de Parkinson: Grupos farmacológicos e intervenciones no farmacológicas
2. Molecular basis of the neurodegenerative disorders
3. Ropinirole for the treatment of early Parkinson's disease
4. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: A clinical pharmacologic approach
5. A five-year study of incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa
6. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled-trial
7. Comparison of immediate-release and controlled release carbidopa-levodopa in Parkinson's disease. A multicenter 5-year study
8. Pergolide versus bromocriptine for levodopa-induced motor complications in Parkinson's disease
9. The rationale for the use of dopamine agonists in Parkinson's disease
10. A six-month study of pergolide and levodopa in de novo Parkinson's disease patients
11. Log term efficacy of pergolide monotherapy in early-stage Parkinson's disease (PD). One-year interim analysis of a 3-year double-blind randomized study of pergolide versus levodopa
12. Hallucinosis in idiopathic Parkinson's disease
13. Early dopaminergic drug-induced hallucinations in parkinsonian patients
14. Accuracy of the clinical diagnosis of Lewy body disease, Parkinson's disease and dementia with Lewy bodies: A clinicopathologic study
15. Toxic effects of L-dopa in mesencephalic cells cultures: Protection with antioxidants
16. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
17. Does ageing aggravate parkinsonian disability?
18. A comparison of clinical and pathological features of young and old-onset Parkinson's disease
19. Does long-term aggravation of Parkinson's disease result from nondopaminergic lesions?
20. An [18F] dopa-PET and clinical study of the rate of progression in Parkinson's disease
21. A clinicopathological study of 100 cases of Parkinson's disease
22. Clinical observations on the rate of progression of idiopathic parkinsonism
23. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease
24. The use of dopamine agonists in very elderly patients with Parkinson's disease
25. Antioxidant properties of bromocriptine, a dopamine agonist
26. Levodopa. Is toxicity a myth?
27. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
28. New lessons from old drugs: Amantadine and Parkinson's disease
29. The response to levodopa in Parkinson's disease: Imposing pharmacological law and order
30. Pharmacodynamics of the long-duration response to levodopa in PD
31. Is stimulation of D-1 and D-2 dopamine receptors important for optimal motor functioning in Parkinson's disease?
32. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress
33. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five-year follow-up
34. Early combination of bromocriptine and levodopa in Parkinson's disease: A prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage
35. Pergolide monotherapy in the treatment of early Parkinson's disease: A randomized, controlled study
36. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
37. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study
38. A placebo controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease
39. Ropinirole for the treatment of early Parkinson disease: A 12-month experience
40. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease
41. Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa controlled study
42. Ropinirole in the treatment of levodopa induced motor fluctuations in patients with Parkinson's disease
43. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
44. Treatment of Parkinson's disease should begin with a dopamine agonist
45. The initial treatment of Parkinson's disease should begin with levodopa
46. Parkinson's disease
47. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?
48. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease
49. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
50. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe
51. The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins
52. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease
53. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients
54. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells
55. A Drosophila model of Parkinson's disease
56. Association between early-onset Parkinson's disease and mutations in the parkin gene
57. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
58. Dopaminergic neurons degenerate by apoptosis in Parkinson's disease
59. Apoptosis in neurodegenerative disease: The role of mitochondria
60. The impact of deprenyl and tocopherol treatment on Parkinson's disease in Datatop subjects not requiring levodopa
61. Impact of deprenyl and tocopherol treatment on Parkinson's disease in Datatop patients requiring levodopa
62. Dopamine agonists and neuroprotection in Parkinson's disease
63. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro
64. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease
65. Evidence to support early levodopa therapy in Parkinson disease
66. Effect of age at onset on progression and mortality in Parkinson's disease
67. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras
68. The spectrum of levodopa-related fluctuations in Parkinson's disease
69. Levodopa in the treatment of Parkinson's disease: A consensus meeting
70. The response to levodopa in Parkinson's disease: Imposing pharmacologic law and order
71. On-off phenomenon: Relation to levodopa pharmacokinetics and pharmacodynamics
72. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part I
73. Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II
74. A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: A five year follow up
75. Pramipexole vs levodopa as initial treatment for Parkinson disease - A randomized controlled trial
76. The functional anatomy of basal ganglia disorders
77. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: In situ hybridization histochemical analysis
78. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model
79. Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism
80. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications
81. Continuous and intermittent levodopa differentially affect basal ganglia function
82. Chronic treatment with L-dopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding
83. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset
84. Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys
85. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys
86. Dopamine receptors: From structure to behavior
87. Molecular basis of levodopa-induced dyskinesias
88. Preproenkephalin mRNA expression in the caudateputamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-dopa therapy
89. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease
90. Continuous dopamine-receptor stimulation in the early treatment of Parkinson's disease
91. A rationale for using dopamine agonists as primary symptomatic therapy in Parkinson's disease
92. Dopaminergic agonists in the treatment of Parkinson's disease: A review
93. Comparative review of dopamine receptor agonists in Parkinson's disease
94. Preclinical pharmacology of ropinirole (SK&F 101468-A): A novel dopamine D2 agonist
95. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease
96. Striatal mechanisms and pathogenesis of parkinsonian signs and motor complications
97. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys
98. Ropinirole for the treatment of early Parkinson's disease
99. Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist
100. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain
101. Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia
102. Amantadine in Parkinson's disease
103. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease
104. Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits
105. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys
106. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
107. Amantadine for levodopa-induced dyskinesias: A 1-year follow-up study
108. Dopamine receptor stimulation: Biobehavioral and biochemical consequences
109. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease
110. Clinical implications of sustained dopaminergic stimulation
111. Sleep in patients with Parkinson's disease and normal subjects prior to and following levodopa administration
112. Sleep disturbances in Parkinson's disease
113. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole
114. Hallucinations, REM sleep, and Parkinson's disease: A medical hypothesis